Invasive pneumococcal disease in the Netherlands: Syndromes,outcome and potential vaccine benefits |
| |
Authors: | Angelique G.S.C. Jansen Gerwin D. Rodenburg Sabine C. de Greeff Eelko Hak Reinier H. Veenhoven Lodewijk Spanjaard Leo M. Schouls Elisabeth A.M. Sanders Arie van der Ende |
| |
Affiliation: | 1. Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children''s Hospital, UMC Utrecht, The Netherlands;2. National Institute for Public Health and the Environment, Bilthoven, The Netherlands;3. Julius Center for Health Sciences and Primary Care, UMC Utrecht, The Netherlands;4. Department of Pediatrics, Spaarne Hospital, Haarlem, The Netherlands;5. Academic Medical Center Amsterdam, Center for Infection and Immunity Amsterdam, Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, The Netherlands;6. Department of Epidemiology, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands |
| |
Abstract: | With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for ∼25% of the Dutch population (1275 hospitalized cases) over the period June 2004–June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3–5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60 yrs, from 26 cases in 60–64-yr-olds to 97 cases per 100,000 in persons ≥90 yrs. Beyond the age of 4 yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy. |
| |
Keywords: | Invasive pneumococcal disease Epidemiology Serotype distribution Disease course Outcome |
本文献已被 ScienceDirect 等数据库收录! |
|